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ABSTRACT
Background. The molecular phenotype of circulating tumor
cells (CTCs) was associated with clinical outcome of patients
with breast cancer. CTCs isolated from patients with metastatic
breast cancer (MBC) display a unique microRNA (miRNA)
expression proﬁle. The aim of this study was to enhance the
prognostic accuracy of the CTC phenotype in patients withMBC,
by incorporatingmiRNA into a combined predictionmodel.
Subjects, Materials, and Methods. CTCs were detected by
CellSearch and enriched by magnetic cell sorting. miRNA
deep sequencing and quantitative polymerase chain reac-
tion were used to screen and verify potentially CTC-speciﬁc
miRNA candidates. Patients with MBC were enrolled from
two independent cohorts, and overall survival (OS) and che-
motherapy response were analyzed.
Results. We screened and identiﬁed that miR-106b was an
upregulated molecule in patients with MBC with CTC ≥5/7.5
mL (n = 16) compared with patients with CTC = 0/7.5 mL
(n = 16) and healthy donors (n = 8). The expression of CTC-
speciﬁc miR-106b correlated with vimentin and E-cadherin in
CTC and acted as an independent factor for predicting OS
(hazard ratio 2.157, 95% conﬁdence interval [CI] 1.098–4.239,
p = .026). Although CTC-speciﬁc miR-106b, E-cadherin, and
vimentin showed a prognostic potential independently, the
prognostic performance for OS based on the combination of
three markers was signiﬁcantly enhanced in Cohort 1 (area
under the curve [AUC] 0.752, 95% CI 0.658–0.847, n = 128)
and further validated in Cohort 2 (AUC 0.726, 95% CI
0.595–0.856, n = 91). Besides, a combined model incorporat-
ing miR-106b was associated with therapy response.
Conclusion. The phenotypic assemblies of CTC incorporating
miR-106b show enhanced prognostic accuracy of overall
survival in patients with MBC. The Oncologist 2019;24:1–11
Implications for Practice: In order to enhance the prognostic accuracy of the circulating tumor cell (CTC) phenotype in
patients with metastatic breast cancer (MBC), this study screened and identiﬁed a CTC-speciﬁc microRNA (miRNA), miR-106b,
as an upregulated molecule based on the comparison of miRNA proﬁle between CTCs, primary tumors, and healthy blood
donors. By incorporating miR-106b into a combined prediction model, the prognostic accuracy of the CTC phenotype for
patients with MBC was greatly improved in both the training and validation cohorts. This work provides clinical evidence
supporting the prognostic potential of CTC-speciﬁc miRNA for patients with MBC. These results indicate that developing CTC-
speciﬁc miRNAs as new biomarkers will help to further optimize personalized therapy.
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INTRODUCTION
Metastasis is associated with the presence of peripheral blood
circulating tumor cells (CTCs), which are suggested to be
potential seeds for hematogenous cancer metastasis [1, 2].
Several studies have demonstrated that the presence of CTCs
before the initiation and after the completion of adjuvant che-
motherapy is associated with poor clinical outcome [3, 4]. In
metastatic breast cancer (MBC), the assessment of CTCs before
and shortly after the initiation of chemotherapy may predict
progression-free survival (PFS) and overall survival (OS) [5, 6].
Although the presence of chromosomal alterations conﬁrmed
the malignant nature of CTCs [7, 8], only some are capable
of promoting metastasis [9]. Regarding their individual gene
expression, characterizing the molecular phenotypes of the
CTCs, rather than their blood concentration and/or number, is
essential to further understand their metastatic potential as
well as identify novel markers related to patients’ prognosis.
Epithelial-mesenchymal transition (EMT) is considered to
be the crucial event in the metastatic process of cancer, involv-
ing aberrant expression of the EMT-related molecules and the
acquisition of a migratory mesenchymal phenotype [10]. The
morphological and phenotypical changes of EMT undergone
by cancer cells also exist in CTCs of breast cancer [11]. CTCs
that undergo EMT lose cell-cell contacts and polarity, down-
regulate epithelial-associated genes, and acquire mesenchy-
mal gene expression [12–14]. E-cadherin and vimentin act as
the core protein of the epithelial adherence junction [15, 16].
Several studies have demonstrated that vimentin is expressed
in CTCs of patients with breast cancer [17, 18]. CTCs displaying
upregulated vimentin were associated with clinical response
to therapy and disease progression [19, 20], suggesting that
the molecular phenotype of CTCs including EMT was associ-
ated with the clinical outcome of patients with breast cancer.
It has been reported that CTCs isolated from a cohort of
patients with MBC by the CellSearch Proﬁle Kit display a
unique miRNA expression proﬁle [21], indicating that an exten-
sive miRNA characterization of CTCs will hold great promise
and improve the currently available prognostic models on the
basis of primary tissue. However, little is known regarding the
correlation between the noncoding molecules in CTCs and
EMT-related characteristics as well as their potential clinical
relevance.
In the current study, in order to identify new miRNAs for
CTC phenotype classiﬁcations and enhance the prognostic value
of the CTC phenotype for patients with MBC, we screened the
CTC-speciﬁc miRNAs based on the comparison of miRNA deep
sequencing between CTCs and primary tumors and veriﬁed
miR-106b as a key molecule with the highest upregulation in
CTCs. Furthermore, we quantiﬁed the expression level of miR-
106b in CTCs of patients with MBC and investigated the prog-
nostic role of the CTC phenotype incorporating CTC-speciﬁc
miR-106b for patients withMBC in two independent cohorts.
SUBJECTS, MATERIALS, AND METHODS
Patients
This study enrolled patients initially diagnosed with MBC
between March 2012 and December 2015 in the Sun Yat-sen
Memorial Hospital (SYSMH; Guangzhou, China) and the
Sun Yat-sen University Cancer Center (SYSUCC; Guangzhou,
China). All patients were required to have clinical and
radiologic evidence of MBC with either measurable or eva-
luable disease. Metastatic diseases were measured or evalu-
ated using clinical and radiological methods in accordance
with the RECIST version 1.1 criteria. All patients had Eastern
Cooperative Oncology Group performance status 0–1.
Prior adjuvant chemotherapy and/or hormone treatment
were allowed. The estrogen receptor (ER) and the progester-
one receptor (PR) status of the primary tumors were deter-
mined by immunohistochemistry. Human epidermal growth
receptor 2 (HER2) expression was evaluated using the
HercepTest (Dako, Denmark) and assessed according to the
DAKO-score; samples with score 2+ were further analyzed by
ﬂuorescent in situ hybridization.
Before treatment, all patients had a complete clinical and
laboratory evaluation, chest and abdominal computed
tomography scans, and whole-body bone scan. Reassessment
of the disease status was also performed every 8 weeks.
Response to treatment was assessed using the RECIST 1.1
criteria.
Blood Sample Collection
Prior to the administration of systemic therapy, 7.5 mL of
blood was drawn from patients in CellSave tubes (Veridex
LLC) for CTC enumeration by CellSearch. CTC enumeration and
characterization were conﬁrmed by independent reviewers.
Fifty milliliters of fresh blood was collected for sorting
and enriching CTCs using magnetic activated cell sorting
(MACS; Miltenyi Biotec, Bergisch Gladbach, Germany) if CTC
count ≥5/7.5 mL after primary enumeration. To avoid con-
tamination with epithelial cells from the skin, all blood sam-
ples were obtained at the middle of vein puncture after the
ﬁrst 1 mL of blood was discarded.
Enumeration of CTCs Using the CellSearch System
Enumeration of CTCs was performed at the central labora-
tory of our institution using the U.S. Food and Drug
Administration-approved CellSearch system by using CEL-
LSEARCH Circulating Tumor Cell Kit. The process has been
described in the manufacturer’s instructions. Unfavorable
CTC enumeration was deﬁned as ≥5 CTCs in 7.5 ml of periph-
eral blood.
CTCs Sorting and Enrichment
CTCs were isolated from 50 mL EDTA blood by MACS. Brieﬂy,
samples were layered over Ficoll-Paque (1.077, density) and
centrifuged at 400g for 30 minutes at room temperature;
peripheral blood mononuclear cells (PBMCs) were present at
the interphase. PBMCs were resuspended at 5 × 107 cells in
300 mL solution containing 100 mL FcR Blocking Reagent
(130-059-901, Miltenyi Biotec), 100 mL CD45 Microbeads
(130-045-801, Miltenyi Biotec), and 100 mL CD15 Microbeads
(130-091-058, Miltenyi Biotec). After depletion of CD45+ and
CD15+ cells by magnetic separation with autoMACS Pro Sep-
arator, 100 mL CD326 (also known as Epithelial Cell Adhesion
Molecule, EpCAM) Microbeads (130-095-500, Miltenyi Bio-
tec) per 5 × 107 cells was added for 30-minute incubation
at 4C. The magnetically charged CD326+ and CD326- cell
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fractions were eluted as the EpCAM+ and EpCAM− CTCs. The
purity of epithelial cells was determined by immunoﬂuores-
cent staining with an anticytokeratin antibody (10 μg/mL,
ab41825; Abcam, UK), which was more than 95%. For a cell
to be identiﬁed as a CTC, it had to meet two criteria:
(a) positive staining for a tumor-speciﬁc marker by immuno-
cytochemistry (cytokeratin) and (b) positive scoring upon
review by the cytopathologist.
Screening and Quantiﬁcation of CTC-Speciﬁc miRNAs
Total RNA was extracted from primary tumors and CTCs
enriched by EpCAM-based CellSearch from 50 mL of blood of
six patients with MBC. MiRNA Deep Sequencing on Illumina
HiSeq 2500 sequencing platform with 10 M reads (Illumina,
San Diego, CA; Guangzhou RiboBio Company, Guangzhou,
China) was used to screen CTC-speciﬁc miRNA candidates
from these samples. Real-time polymerase chain reaction
(PCR) was used to quantify CTC-speciﬁc miRNAs expression
levels. Complementary DNA (cDNA) was generated using the
miScript Reverse Transcription (RT) Kit (Qiagen GmbH,
Hilden, Germany). Brieﬂy, real-time PCR was performed using
the miScript SYBR Green PCR Kit (Qiagen) on an Mx3005P
QPCR System (Stratagene, La Jolla, CA). The speciﬁcity of this
RT-PCR technique was conﬁrmed by dissociation curve analy-
sis using the Mx3005P QPCR System (Stratagene) according
to the manufacturer’s instruction. Bulge-Loop miRNA primers
were offered by RiboBio Company, Guangzhou, China. Tran-
scripts of U6 small RNA were quantiﬁed for normalization of
the levels of miRNAs [22, 23].
ΔCt values were used to normalize and calculate the
concentration of miRNAs. The experiment was repeated
three times and the data were analyzed blind. The 2−ΔΔCt
value was the difference in ΔCt between patients and con-
trols, and the normalized miRNAs expression levels were
calculated with the formula 2−ΔΔCt.
Quantiﬁcation of EMT-Related Molecules in CTCs
RNA was extracted from CTCs using the Recover All Total
Nucleic Acid Isolation Kit (Ambion, Life Technologies, Carls-
bad, CA) as described. Total RNA from each sample was
quantiﬁed by NanoDrop ND-1000 (ThermoFisher). cDNA was
synthesized from total RNA using the ImProm-II Reverse
Transcriptase system (Promega) according to the manufac-
turer’s protocol. The mRNA levels were measured by quanti-
tative real-time PCR, which was performed in an ABI 7500
Real-time PCR system using SYBR Green PCR Master Mix
(Applied Biosystems). Glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) were used as standards for the absolute quanti-
ﬁcation of each cDNA. The amount of target gene expression
could be calculated from the standard curve, which plotted
the cycle threshold (Ct) value and the corresponding value of
the amount of input DNA. The quantitative PCR primers used
are listed in supplemental online Table 1.
Statistical Analysis
Statistical analyses were performed using SPSS version 17.0
(SPSS, Chicago, IL). Student’s t test and one-way analysis of
variance analyses were performed to analyze the differ-
ences between the groups. A chi-square test was applied to
analyze the relationship between miR-106b expression and
EMT-related molecules of CTC. OS was deﬁned as the time
elapsed between inclusion and death from any cause. Sur-
vival curves were plotted according to the Kaplan-Meier
method. Statistical signiﬁcance between survival curves was
assessed using the log-rank test. Multivariate analysis was
done by the Cox proportional hazards model with prognos-
tic factors. The Cox regression model was performed for
the combined three prognostic factors. The receiver operat-
ing characteristic (ROC) curves were employed to test the
sensitivity and speciﬁcity of variables in predicting OS. For
the other analyses, a p value of <.05 was considered to be
statistically signiﬁcant.
RESULTS
Patient Characteristics
From March 2012 to December 2015, a total of 128 patients
with MBC in SYSMH (Cohort 1) and 91 patients with MBC in
SYSUCC (Cohort 2) were enrolled in this study. Cohort 1 was
used as a training set in our study, whereas Cohort 2 was
used as a validation set. A ﬂow chart outlining the selection
of patients from SYSMH (Cohort 1) is shown in supplemental
online Figure 1. The patients from Cohort 2 were selected
and investigated in a similar manner as those in Cohort 1. All
enrolled patients had ﬁve or more CTCs in 7.5 mL of blood
enumerated at baseline section by CellSearch. Patient charac-
teristics of Cohort 1 and Cohort 2 at baseline are summarized
in Table 1 and supplemental online Table 2. The median age
(range) at initial diagnosis of these patients with breast can-
cer was 51 (23–69) years, and the median age at study entry
was 56 (29–72) years. Notably, the majority of patients had
ER-positive (ER+; 96/128, 75%), PR-positive (87/128, 67.9%),
and HER2-negative (101/128, 78.9%) primary tumors. In most
patients, the tumor had disseminated into more than one
organ (87/128, 68%), and approximately half of the patients
had both bone and visceral metastases (70/128, 54.7%). All
patients received front-line chemotherapy. Among them,
16 (12.5%) patients received ﬂuorouracil, epirubicin, and
cyclophosphamide/epirubicin and cyclophosphamide regi-
men, 42 (32.8%) patients received epirubicin and taxane che-
motherapy regimen, and 53 (41.4 %) patients received
taxane chemotherapy regimen. Moreover, there were 17
(13.3 %) patients who received chemotherapy regimens
without epirubicin and taxane. In addition, 24 of 27 (88.9 %)
patients with HER2-positive tumors received anti-HER2 ther-
apy (trastuzumab or lapatinib or both). All ER+ patients
received endocrine therapy. Follow-up data were available
for 128 patients with a median follow-up of 13.1 months
(range, 2.5–29.7 months) for OS.
Selection of Potentially CTC-Speciﬁc miRNA
Candidates
To found out CTC-speciﬁc miRNAs, we ﬁrst used an MiRNA
Deep Sequencing to screen the miRNA candidates in primary
tumors and CTCs enriched by EpCAM-based CellSearch from
50 mL of blood of six patients with MBC (supplemental online
Table 3) among 2,588 miRNAs in the MiRNA Sequencing
(Fig. 1) based on the following standards: fold changes were
more than 5 folds compared with the primary tumor in all six
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patients with MBC, basal expression level of normalized inten-
sity were more than 100, miRNA candidates were reported to
play functional roles in promoting breast cancer metastasis.
Finally, 10 miRNAs were picked out as upregulated candidates
(supplemental online Table 4), and these 10 upregulated
miRNAs could be sensitivity nonhomogeneously ampliﬁed
with a minimum number of miRNA in sensitive multiplex
stem-loop cDNA approach with the TaqMan-based linear pre-
ampliﬁcation method. We further compared these 10 miRNA
transcript levels in cells enriched by MACS (CMs) of blood
from healthy blood donors (HBDs; n = 8) and CTC samples
from patients with MBC (n = 32) by RT-PCR (supplemental
online Table 3). We observed that only miR-106b was signiﬁ-
cantly upregulated in CTCs ≥5 samples (n = 16) compared
with CTCs = 0 samples (n = 16) and HBD-CSs (supplemental
online Table 5). This suggests that miR-106b might be a
potentially CTC-speciﬁc miRNA, and we selected it for our
further investigation.
Association of miR-106b and EMT-Related Molecules
in CTC
It has been reported that miR-106b regulates the EMT of
cancer cells and promotes tumor progression [24]. It is also
noted that, upon EMT inducement, cancer cells exhibit mor-
phological changes and a couple of EMT-related molecules
including E-cadherin, vimentin, ck19, Snail, and N-cadherin.
Therefore, we further quantiﬁed the expression level of
miR-106b and the above EMT-related molecules in CTCs
using quantitative RT-PCR, and analyzed their correlations.
As a result, we found that the expression of CTC-speciﬁc
miR-106b was positively correlated with vimentin (r = .687,
p < .001; Fig. 2A) and negatively correlated with the expres-
sion level of E-cadherin (r = −.672, p < .001; Fig. 2B) but had
no signiﬁcant correlations with other molecules (supple-
mental online Fig. 2). In subtype analysis, we found that the
expression level of CTC-speciﬁc miR-106b was signiﬁcantly
higher in patients with triple-negative breast cancer (TNBC)
compared with non-TNBC subtypes (p = .011; Fig. 2C). These
data suggest that miR-106b is a speciﬁc biomarker for EMT-
related phenotype of CTC.
Association of CTC-Speciﬁc miR-106b, E-cadherin,
and Vimentin with Clinical Outcome
It is well known that the number and phenotypes of CTC
correlates with prognosis of patients with MBC [17, 25].
Table 1. Characteristics of patients in Cohort 1 and
Cohort 2
Characteristics
Cohort 1,
n (%)
Cohort 2,
n (%) Total p value
ER status .01
Negative 32 (25.0) 10 (11.0) 42
Positive 96 (75.0) 81 (89.0) 177
PR status .003
Negative 41 (32.0) 13 (14.3) 54
Positive 87 (68.0) 78 (85.7) 165
HER2 status .286
Negative 101 (78.9) 77 (84.6) 178
Positive 27 (21.1) 14 (15.4) 41
KI67 status .244
Negative 49 (38.3) 42 (46.2) 91
Positive 79 (61.7) 49 (53.8) 128
Metastasis site .906
Bone 18 (14.1) 12 (13.2) 30
Visceral/local 40 (31.3) 31 (34.1) 71
Both 70 (54.7) 48 (52.7) 118
Number of
metastasis sites
.844
1 41 (32.0) 28 (30.8) 69
≥2 87 (68.0) 63 (69.2) 150
Molecular subtype .331
Luminal A 41 (32.0) 29 (31.9) 70
Luminal B 56 (43.8) 31 (34.1) 87
HER2+ 9 (7.0) 7 (7.7) 16
TNBC 22 (17.2) 24 (26.4) 46
Treatment
before study
Hormonal
therapy
.01
Yes 96 (75.0) 81 (89.0) 177
No 32 (25.0) 10 (11.0) 42
Front-line
chemotherapy
.063
FEC/EC 16 (12.5) 11 (12.1) 27
TE 42 (32.8) 29 (31.9) 71
T 53 (41.4) 38 (41.8) 91
Other 17 (13.3) 13 (14.3) 30
Anti-HER2 therapy
(trastuzumab,
lapatinib)
.185
Yes 24 (18.8) 11 (12.1) 35
No 104 (81.3) 80 (87.9) 184
Radiological
response
after ﬁrst
cycle of
chemotherapy
.924
Non-PD 81 (63.3) 57 (62.6) 138
PD 47 (36.7) 34 (37.4) 81
(continued)
Table 1. (continued)
Characteristics
Cohort 1,
n (%)
Cohort 2,
n (%) Total p value
Survival status <.0001
Alive 47 (36.7) 77 (84.6) 124
Dead 81 (63.3) 14 (15.4) 95
p value is calculated by chi-square test or Fisher’s exact test.
Abbreviations: E, epirubicin; EC, epirubicin combined with cyclo-
phosphamide; ER, estrogen receptor; FEC, epirubicin combined with
cyclophosphamide with ﬂuorouracil; HER2, human epidermal
growth receptor 2; PD, progressive disease; PR, progesterone recep-
tor; T, docetaxel; TE, epirubicin combined with docetaxel; TNBC,
triple-negative breast cancer.
© 2019 The Authors.
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Therefore, we further investigated the clinical relevance of
the above CTC-speciﬁc molecules with the prognosis of
patients with MBC. First, we individually assessed the prog-
nostic performance of CTC-speciﬁc miR-106b, E-cadherin, and
vimentin by plotting the ROC curve in 128 patients. Consistent
with other studies [26, 27], in our study, CTC-speciﬁc E-
cadherin and vimentin showed a prognostic value for patients
withMBC, respectively (E-cadherin, AUC = 0.637, Fig. 3A;
vimentin, AUC = 0.642, Fig. 3B). The lower-expression group
of E-cadherin (hazard ratio [HR] 1.624, 95% conﬁdence inter-
val [CI] 1.017–2.594, p = .042; Fig. 3C) and higher-expression
group of vimentin (HR 1.993, 95% CI 1.218–3.259, p = .006;
Fig. 3D) showed poorer OS in Kaplan-Meier curve analysis.
Interestingly, higher prognostic performance of CTC-speciﬁc
miR-106b for patients with MBC was observed in ROC analy-
sis (AUC = 0.670, 95% CI 0.572–0.769; Fig. 3E). In order to
further analyze the association between CTC-speciﬁc miR-
106b and prognosis, an optimal cutoff value (0.0105) was
Figure 1. MiRNA Deep Sequencing reveals differentially expressed microRNAs between primary tumors and CTCs from six patients
with metastatic breast cancer.
Abbreviations: CTCs, circulating tumor cells; P, patient; PTs, primary tumors.
Table 2. Univariate and multivariate analysis for overall survival
Variables
Univariate analysis Multivariate analysis
HR
95% CI
p value HR
95% CI
p valueLower Upper Lower Upper
ER status (positive vs. negative) 0.73 0.42 1.26 .254 0.935 0.522 1.677 .822
PR status (positive vs. negative) 1.03 0.52 2.07 .925 0.803 0.385 1.676 .559
HER2 status (positive vs. negative) 1.55 0.92 2.62 .098 1.37 0.771 2.435 .283
Ki67 status (≥14% vs. <14%) 0.91 0.58 1.43 .687 0.756 0.47 1.216 .248
Metastasis site (visceral vs. bone) 1.52 1.16 1.96 .002 0.781 0.56 1.089 .144
Number of metastasis site (≥2 vs. 1) 1.29 0.81 2.04 .282 1.162 0.676 1.998 .588
E-cadherin 1.624 1.017 2.594 .042 1.45 0.891 2.36 .135
Vimentin 1.993 1.218 3.259 .006 1.345 0.765 2.364 .304
miR-106b (high- vs. low-expression) 2.707 1.463 5.008 .002 2.157 1.098 4.239 .026
p value is calculated by chi-square test or Fisher’s exact test.
Abbreviations: CI, conﬁdence interval; ER, estrogen receptor; HER2, human epidermal growth receptor 2; HR, hazard ratio; PR, progesterone
receptor.
© 2019 The Authors.
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determined by ROC analysis and Youden index calculated
by sensitivity and speciﬁcity, which was widely used for
determination of optimal cutoff value in diagnostic test and
prognosis prediction by other studies [28]. Based on this cut-
off value, 128 patients with MBC of Cohort 1 and 91 of
Cohort 2 were divided into miR-106 high-expression and
low-expression subgroups. As shown by Kaplan-Meier curve
analysis, the miR-106 high-expression group was correlated
with a poorer OS (HR 2.707, 95% CI 1.463–5.008, p = .002;
Fig. 3F), compared with the low-expression group.
In addition, univariate analysis found that patients with
visceral metastasis (HR 1.52, 95% CI 1.16–1.96, p = .002), high
expression of miR-106 and vimentin, and low expression of
E-cadherin were more likely to have poor OS. However, in
multivariate analysis, only CTC-speciﬁc miR-106b was an
independent factor for predicting OS (HR 2.157, 95% CI
1.098–4.239, p = .026; Table 2).
Assessment and Validation of the Prognostic
Accuracy of the Three-Molecule Combination
Including CTC-Speciﬁc miR-106b, E-cadherin, and
Vimentin
Because of the limited prognostic accuracy of CTC-speciﬁc
E-cadherin and vimentin and relative higher prognostic per-
formance of CTC-speciﬁc miR-106b for patients with MBC,
we further incorporated miR-106b into a Cox regression
model to compare the prognostic accuracy between the
multimolecule assemblies and single biomarker. As a result,
we found that the new model combining the expression of
three molecules was signiﬁcantly more accurate than any
other single biomarker evaluated in our study for predicting
overall survival (AUC 0.752, 95% CI 0.658–0.847; Fig. 4A).
This result was further validated in Cohort 2. In Cohort
2, the clinicopathological characterization of 91 selected
patients with MBC was similar to that of patients from
SYSMH (Cohort 1), including 81 (89%) ER-positive patients
and 14 (15.4%) HER2-positive patients (supplemental online
Table 2). Notably, most patients were Luminal subtype (60 of
91, 65.9%) and triple negative (24 of 91, 26.4%), and only
7 patients were HER2+ subtype. In addition, we found that
the distribution of miR-106b expression in Cohort 2 was simi-
lar to Cohort 1 (supplemental online Fig. 3). Therefore, we
used the same cutoff value to divide Cohort 2 into miR-106b
high- and low-expression subgroups. We veriﬁed that the
new model combining the expression of three molecules
also showed a signiﬁcantly prognostic value for predicting
overall survival in the validation cohort (AUC 0.726, 95% CI
0.595–0.856; Fig. 4B).
In subtype analysis, we made ROC analysis to test the
prognostic accuracy in all 219 patients (Cohort 1 and Cohort 2)
and found that the prognostic accuracy of the three-molecule
combination including CTC-speciﬁc miR-106b, E-cadherin, and
vimentin was still signiﬁcant in luminal subtypes (AUC = 0.693,
95% CI 0.609–0.776, n = 157; supplemental online Fig. 4A) and
the TNBC subtype (AUC = 0.710, 95% CI 0.522–0.898, n = 48;
supplemental online Fig. 4B).
Association of the Three-Molecule Combination and
Clinical Response
The correlation between expression of CTC-speciﬁc miR-
106b and clinical response was further analyzed. Patients
with progression at the radiological examination following
two cycles of ﬁrst-line chemotherapy showed higher expres-
sion of CTC-speciﬁc miR-106b (Fig. 5A, p < .01). Further
analysis showed that the combination of CTC-speciﬁc miR-
106b containing E-cadherin and vimentin could signiﬁcantly
predict the clinical response to therapy in patients with
MBC (AUC 0.691, 95% CI 0.598–0.784; Fig. 5B). This result
was further validated in Cohort 2 with 91 patients with
MBC (AUC 0.661, 95% CI 0.519–0.804; Fig. 5C).
DISCUSSION
In this study, we found that miR-106b was signiﬁcantly
upregulated in CTCs compared with primary tumor and
CMs of blood from HBDs. The expression level of CTC-
speciﬁc miR-106b was correlated with EMT-related pheno-
type of CTC. In addition, high expression of CTC-speciﬁc
miR-106b was correlated with a poor OS and acted as an
independent factor for predicting OS. More importantly, by
incorporating miRNA expressions into a combined predic-
tion model, the prognostic accuracy of CTC phenotype in
patients with MBC was signiﬁcantly enhanced.
Quantiﬁcation of CTCs in breast [29], colorectal [30], and
pancreatic cancer [31] has been shown to correlate with sur-
vival. However, less than 0.01% of CTCs seem to survive in
the target organ for colonization and subsequent growth.
An intriguing area of active research is whether molecular
characterization of CTC before clinical manifestation could
better predict metastatic risk and facilitate individualized
Figure 2. MiR-106b is a speciﬁc biomarker for CTC phenotypes. Correlation of the expression of miR-106b with vimentin (A,
n = 128) and E-cadherin (B, n = 128). (C): Quantiﬁcation of miR-106b by real-time quantitative polymerase chain reaction in TNBCs
(n = 16) and non-TNBCs (n = 112).
Abbreviations: CTC, circulating tumor cell; TNBCs, triple-negative breast cancers.
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therapeutic strategies to inhibit target organ colonization
and metastatic growth. Of note, the activation of an EMT is
favorable for the CTC population [32]. It has been reported
that the presence of mesenchymal markers such as vimentin
on CTCs more accurately predicted worse prognosis than the
expression of cytokeratin [20, 33].
In our study, we found that CTC-speciﬁc miR106b was
positively related to the expression level of vimentin in
CTCs. It has been reported that overexpression of miR-106b
was observed in a variety of human tumors, which plays an
oncogenic role in tumor progression and prognosis, includ-
ing colorectal cancer [34, 35], gastric cancer [36, 37], hepa-
tocellular carcinoma [38, 39], glioma tumors [40], renal cell
carcinoma [41, 42], and head and neck squamous cell carci-
nomas [43]. MiR-106b plays a functional role in promoting
proliferation, migration, and invasion of cancer cells both
in vitro and in vivo [44–46]. Clinical data show that high
expression level of miR-106b is associated with metastasis
and poor prognosis [34, 47]. Consistent with these ﬁndings,
we found that patients with MBC with high CTC-speciﬁc
miR-106b expression had shorter progression-free survival,
suggesting that this phenotypic attribute becomes salient
when considering each of the steps in the cascade of events
required for metastatic success.
Our clinical data showed that in both the training and
validation set, the combination of CTC-speciﬁc miR-106b,
E-cadherin, and vimentin was signiﬁcantly more accurate
than any single molecule assessed in our study for predicting
overall survival and clinical response to therapy. Several lines
of explanation may be responsible for this enhanced prog-
nostic value of this molecule combination. First, molecular
phenotypes of CTCs were associated with various behavior
Figure 3. Association of circulating tumor cell (CTC)-speciﬁc molecules with clinical outcome. Receiver operating characteristic cur-
ves evaluated the prognostic accuracy for E-cadherin (A), vimentin (B), and miR-106b (E) in CTCs. Kaplan-Meier survival curves for
E-cadherin (C), vimentin (D), and miR-106b (F) in CTCs.
Abbreviation: AUC, area under the curve.
© 2019 The Authors.
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of cancer cells including anoikis resistance metastasis and
therapeutic resistance. It has been reported that miR-106b
promotes anoikis resistance [24] and EMT processes in
breast cancer cells by targeting RB [48] and Snail gene [49].
Acquisition of a more malignant phenotype for CTC might
easily explain the resistance to elimination strategies such as
chemotherapy, local antigrowth signaling, and immune attack
by the host. Second, according to our results, CTC-speciﬁc
miR-106b was expressed at a higher level in mesenchymal-
like CTCs that highly expressed vimentin, suggesting that
there is a coordination between miR-106b and EMT-related
phenotypes of CTCs. Third, mechanically, our previous study
demonstrated that miR-106b determines the effect of trans-
forming growth factor β, a key EMT inducer, on the tumor
behavior of breast cancer cells by targeting RB [48]. Several
studies have also demonstrated that a variety of genes were
identiﬁed as the target of miR-106b including caspase-7 [47],
PTEN [50], and Smad7 [17, 20, 51], which contribute to miR-
106b-mediated EMT of cancer cells. In this scenario, CTC-
speciﬁc miR-106b plays a critical role in regulating the EMT
of CTCs, indicating that CTCs with higher expression of
vimentin and miR-106b show a higher motility in the blood-
stream and more easily interact with the intravascular micro-
environment, extravagate through the microvasculature, and
interact with the metastatic microenvironment of target
organs. Consistent with this notion, the clinical relevance was
further demonstrated by our clinical data that CTC-speciﬁc
miR-106b was an independent factor for predicting overall
survival and therapy response of patients with MBC. These
are responsible for incorporating miR-106b into the molecu-
lar phenotype of CTC and could further enhance the prognos-
tic accuracy of CTC.
Increasing evidence shows that the phenotype of CTCs
was related to disease prognosis and holds great promise in
guiding treatment decision making in patients with breast
cancer. Therefore, identifying new molecules to reﬁne the
molecular phenotype of CTC will help the clinicians to better
formulate appropriate therapy strategies for individual
patients. The EMT-related biomarkers including vimentin and
E-cadherin have been reported to detect the phenotype of
CTC [17, 20, 52], and CTCs displaying upregulated vimentin
were associated with clinical response to therapy and disease
progression [17, 20]. With the development of sequencing
technology and in-depth understanding of the mechanism for
cancer progression, it is necessary to take into account more
gene information and then characterize the detailed molecular
phenotype of CTC to improve the prognostic performance of
established CTC-related clinical models. In our study, we
screened and validated that miR-106b was an upregulated bio-
marker in patients with MBC. The expression of CTC-speciﬁc
miR-106b was correlated with vimentin and E-cadherin in CTC
and acted as an independent factor for predicting OS in
patients with MBC. The prognostic performance for OS based
on the combination of three markers (miR-106b, E-cadherin,
and vimentin) was signiﬁcantly enhanced and can be fur-
ther validated in an external validation cohort. Our results
suggest that incorporating miRNA into molecular pheno-
types of circulating tumor cells enhances the prognostic
accuracy. In addition, this new model is feasible, efﬁcient,
and cost-effective for clinical application.
In our study, there was still some weakness that deserves
to be acknowledged. First, the molecular mechanisms by which
miR-106b and EMT-related molecules in CTCs regulate tumor
progression were not presented in this study. However, several
Figure 4. Comparison of the prognostic accuracy of single and combined factors. (A): Training set. (B): Validation set.
Abbreviations: AUC, area under the curve; CI, conﬁdence interval.
© 2019 The Authors.
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reasons are responsible for this limitation. As far as we know,
the isolation and enrichment as well as ex vivo culture of viable
CTCs are still technically challenging, and the frequency of CTC
in the peripheral blood of patients with solid tumors varies
among individual patients with different prior systemic thera-
pies. In recent years, although a few papers reported that the
genome alternation of CTC lines and suspended cancer cells
may be related to the drug sensitivity in both in vitro and xeno-
grafts models in breast cancer [53], the evidence is indirect and
not strong enough because of the above limitations. Second,
the downstream targeted molecules of miR-106b related to
EMT should be further tested in our future studies.
CONCLUSION
Our work provides clinical evidence supporting the prognos-
tic potential of CTC-speciﬁc miRNA for patients with MBC.
These results indicate that developing CTC-speciﬁc miRNAs
as new biomarkers will help to further optimize personal-
ized therapy.
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